MARKET

CGEM

CGEM

Cullinan Oncology Inc
NASDAQ
19.60
-0.03
-0.15%
After Hours: 22.42 +2.82 +14.39% 19:59 08/12 EDT
OPEN
19.61
PREV CLOSE
19.63
HIGH
19.94
LOW
19.39
VOLUME
675.79K
TURNOVER
--
52 WEEK HIGH
19.94
52 WEEK LOW
5.68
MARKET CAP
1.26B
P/E (TTM)
-5.7512
1D
5D
1M
3M
1Y
5Y
1D
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Barchart · 6h ago
Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH
NASDAQ · 17h ago
Cullinan Therapeutics (CGEM) Wins FDA Backing For CLN 049, Is The Upside Already Priced In?
Simply Wall St · 1d ago
Cullinan Oncology: Buy Rating Reaffirmed with Unchanged $30 Price Target on Robust Pipeline and Strong Cash Position
TipRanks · 2d ago
Weekly Report: what happened at CGEM last week (0803-0807)?
Weekly Report · 2d ago
Analysts Are Bullish on These Healthcare Stocks: Mesoblast Limited (MEOBF), Cullinan Management (CGEM)
TipRanks · 6d ago
Cullinan Maintained at Buy as Advancing Autoimmune and Oncology Pipeline Supports Unchanged $36 Price Target
TipRanks · 6d ago
Cullinan Therapeutics: Q2 Earnings Snapshot
Barchart · 6d ago
More
About CGEM
Cullinan Therapeutics, Inc. is a biopharmaceutical company. It has built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in autoimmune diseases and cancer. Its portfolio includes a range of modalities. Its pipeline includes CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. CLN-978 is a CD19xCD3 T cell engager being developed for autoimmune diseases. CLN-619 is a monoclonal antibody that stabilizes expression of MICA/B on the tumor cell surface to promote tumor cell lysis mediated by cytotoxic innate and adaptive immune cells. Zipalertinib (CLN-081/TAS6417) is an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor. CLN-049 is a FLT3xCD3 T cell engaging bispecific antibody. CLN-617 is a fusion protein combining two potent antitumor cytokines, interleukin-2 and interleukin-12 with tumor retention domains for the treatment of solid tumors.

Webull offers Cullinan Therapeutics Inc stock information, including NASDAQ: CGEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGEM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGEM stock methods without spending real money on the virtual paper trading platform.